№90. Immunotherapy : What can? What to expect? What to beware of?

Immunologic aspects of tumor biology

DOI 10.31917/2302063

N.M. Volkov
What should we consider besides immune checkpoint drugs on the way to improvement of the efficacy?

DOI 10.31917/2302072

F.V. Moiseenko
Biomarkers predicting the effect of immunotherapy: what you need to know in practice?

DOI 10.31917/2302081

A.M. Konstantinova
The emerging field of checkpoint inhibitors

DOI 10.31917/2302093

V.A. Chubenko
Possibilities of intraluminal photodynamic therapy in oncology (review)

DOI 10.31917/2302100

A.E. Akkalaeva, V.V. Klimenko, A.A. Avanesyan, V.V. Egorenkov, A.A. Bogdanov, V.M. Moiseyenko
Multifactorial analysis of the dependence of prescribed diagnostic test systems and purchased targeted drugs on the example of lung adenocarcinoma in St.P.

DOI 10.31917/2302109

D.D. Zelikova, D.S. Yurochkin, S.E. Erdni-Garyaev, A.A. Leshkevich, Z.M. Golant, D.A. Chagin, N.M. Volkov, F.V. Moiseenko, V.M. Moiseenko